IGF-1 LR3: what it is, how it works, risks and combinations

Summary — brief

IGF-1 LR3 (Long R3 Insulin-Like Growth Factor-1) is a modified form of IGF-1 designed to have reduced affinity for IGF-binding proteins (IGFBPs) and therefore significantly longer biological activity compared with "standard" IGF-1. This is achieved by an arginine substitution at position 3 (R3) and the addition of an N-terminal extension ("Long"), which reduces binding to IGFBPs and increases availability to activate the IGF-1 receptor (IGF-1R). In a research context the molecule is used to study anabolic processes, tissue repair and cellular signaling (PI3K/Akt/mTOR; MAPK/ERK). The product is not intended for human use.

What is IGF-1 and what differentiates IGF-1 LR3

IGF-1 is a peptide hormone produced mainly in the liver under the influence of GH (growth hormone), acting paracrinally/endocrinally in multiple tissues. It binds to IGF-1R and initiates cascades linked to cellular growth, differentiation, protein synthesis, glucose transport and tissue remodeling. In plasma a substantial portion of IGF-1 is "buffered" by IGF-binding proteins (IGFBP-1…-6), which limit the free fraction.

• R3: an amino acid substitution (arginine at position 3) that reduces affinity for IGFBPs and increases the free active fraction.
• Long: an N-terminal extension (added amino acids) that further reduces binding to IGFBPs and prolongs functional activity relative to IGF-1.

The practical consequence is a longer and more pronounced biological availability in tissues expressing IGF-1R. Compared with recombinant IGF-1 (rhIGF-1) LR3 differs in pharmacokinetics and tissue dynamics, making it popular for in vitro and in vivo research on anabolism and regeneration.

Mechanism of action and signaling pathways

IGF-1 LR3 binds to IGF-1R, a receptor tyrosine kinase, and primarily activates:

• PI3K/Akt/mTOR – the pathway responsible for protein synthesis, cell survival, inhibition of proteolysis and metabolic regulation (including glucose transport).
• RAS/RAF/MEK/ERK (MAPK) – cell proliferation, differentiation and remodeling.

In skeletal muscle this is associated with activation of satellite cells, myofibrillar protein synthesis, reduced proteolysis and support for recovery after mechanical stress. In connective tissues (tendon/ligaments) preclinical data often indicate accelerated remodeling, and in epithelial tissues – support for wound healing (wound models). It is important to emphasize that projections from animal/cell models are not directly applicable to humans without approved indications and regulatory approval.

Potential benefits (research context)

• Anabolic effect and body composition: scenarios are studied for increasing/preserving lean mass, especially under catabolic stress (caloric deficit, high training volumes).
• Muscle and tendon recovery: model systems report favorable effects on collagen expression and cellular proliferation in tendon tissues; in muscle – support for regeneration after microtrauma.
• Wound healing: accelerated epithelial closure and granulation in preclinical models.
• Metabolic effects: improved glucose uptake in myocytes (insulin-like signaling); this can manifest as lowered blood glucose (risk aspect, see below).

Note: These benefits are hypotheses/observations in a research environment and do not represent medical indications. IGF-1 LR3 is not an approved medicinal product for treatment.

Risks and adverse effects (why a conservative approach is needed)

• Hypoglycaemia: due to insulin-like effects; the risk increases with low carbohydrate intake, missed meals or concurrent influence of other insulinogenic factors. Symptoms: weakness, trembling, sweating, confusion.
• Fluid retention / edema, headache, joint/muscle soreness: often associated with anabolic/proliferative pathways and changes in water-electrolyte balance.
• Potential mitogenic pressure: IGF-1R signaling is proliferative; active neoplasms/unclear tumors are an absolute contraindication in research scenarios.
• Insulin resistance (paradox): chronic, inappropriate exposure/overactivation may lead to adverse metabolic changes in predisposed individuals.
• Anti-doping: manipulations of the GH/IGF-1 axis are subject to bans by WADA; competitive athletes should familiarize themselves with regulations and avoid such agents.
• Regulatory status: product for research use; not intended for human use.

IGF-1 LR3 vs GH secretagogues and Somatropin

• Compared with GH secretagogues (GHRH analogues, ghrelin agonists): secretagogues enhance endogenous, pulsatile GH peaks → secondarily increase IGF-1 within reference ranges. IGF-1 LR3 acts downstream at the receptor directly, without relying on GH pulsatility. This gives a more direct, but less physiological control over signaling.
• Compared with Somatropin (exogenous GH): GH increases IGF-1 via liver and tissues, with systemic effects and a different risk profile; IGF-1 LR3 "bypasses" GH and targets IGF-1R directly. In research this helps separate the role of IGF-1 from GH, but it does not necessarily mean "better" – it is simply a different tool with different control and risks.

Who and when would choose IGF-1 LR3 (research rationale)

• Focus on local regeneration and anabolism: for models aiming to distinguish direct IGF-1R effects on muscle/connective tissues from GH-dependent processes.
• Metabolic hypotheses: study of glucose transport, insulin-like signaling and mTOR regulation under different nutritional states.
• Tissue-specific experiments: in vitro work on myoblasts/fibroblasts/tenocytes for proliferation/differentiation and matrix studies.

In a clinical context for humans it is not approved and is not recommended for use.

Combinations (in a research framework – principles, not recommendations)

• With GH secretagogues (e.g. CJC-1295 without DAC + Ipamorelin): when the aim is to compare the "physiological" GH→IGF-1 axis versus "direct" IGF-1R activation. Concurrent exposure could excessively amplify signaling (↑IGF-1), so the approach is conservative and should have a clear experimental objective.
• With redox support (for example glutathione in research models): to limit oxidative stress under high training/mechanical load on tissues.
• With nutritional protocols: IGF signaling is conditional on amino acid/energy availability; without sufficient substrate the anabolic response is limited.
• Combinations requiring increased caution: exogenous GH, insulin or strong insulinogenic stimuli – increase the risk of hypoglycaemia/overactivation of IGF signaling and adverse effects.

Practical notes for protocols (educational)

• Form and stability: IGF-1 LR3 is supplied as a lyophilized powder for research use. Stability of reconstituted solutions outside a controlled cold chain is limited; the lyophilisate offers more flexibility for transport and storage prior to reconstitution.
• Timing relative to feeding/load: research models often show dependency on nutritional status (availability of amino acids) and exercise stimulus (mechanotransduction).
• Monitoring (in scientific/veterinary models): glucose, signs of fluid retention/headache, changes in behavior/appetite; in a clinical human setting IGF-1/IGFBP profiling would also be required, but again – the product is not for human use.
• Localization: the question "local vs systemic" in research remains debated; even local exposure can have systemic consequences depending on protocol and bioavailability.

When not to use / caution

• Active neoplasms / unclear tumors – IGF-1R is a mitogenic pathway; such scenarios are contraindicated even in experimental settings, unless the protocol is specifically approved and ethically justified.
• History of proliferative diseases without medical supervision – increased risk.
• Severe cardiometabolic conditions, insulin resistance/dysglycaemia – potential for adverse interactions.
• Pregnancy/breastfeeding, minors – not appropriate.
• Athletes – anti-doping regulations (WADA) prohibit manipulations of the GH/IGF-1 axis.
• Outside ethical/regulatory frameworks – IGF-1 LR3 is for research use only.

IGF-1 LR3 in the context of the "Peptides for recovery and anabolics" category

The category includes agents that either modulate the GH–IGF-1 axis (e.g. CJC-1295 without DAC, Sermorelin; ghrelin agonists like Ipamorelin; metabolically targeted analogues such as Tesamorelin), or support recovery through other mechanisms (e.g. Glutathione as a redox "shield"). IGF-1 LR3 is a downstream tool – it directly activates the receptor and allows researchers to investigate specific effects of IGF signaling on tissues, separate from GH pulsatility.

• If the focus is physiological pulsatility, sleep and recovery → CJC-1295 without DAC + Ipamorelin are often considered.
• If the focus is visceral adipose tissue/metabolism → Tesamorelin has robust randomized data in specific populations.
• If the focus is direct IGF-1R-mediated action on muscle/connective tissue → IGF-1 LR3 is a logical research tool, but with distinct risks.

Sources

1. Review on IGF-1 receptor and signaling (PI3K/Akt/mTOR; MAPK): IGF-1R signaling pathways – review.
2. IGF-1 and skeletal muscle/satellite cells: Clemmons DR – IGF-1 in skeletal muscle; Philippou et al. – IGF-1 & muscle repair.
3. IGF-1 and tendon tissue/collagen: IGF-I in tendon healing.
4. IGF-1 and wound healing (epithelial closure): IGF-1 in wound healing – review.
5. mTOR/growth and metabolism – conceptual review: mTOR signaling – Cell review.
6. Anti-doping regulations: WADA Prohibited List.

View IGF-1 LR3 Browse the category